Crohn's Disease and Colitis Trial, Recruiting NCT07456566 Sponsor: University of Michigan Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Crohn's Disease and Colitis Trial, Recruiting

NCT07456566
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Inflammatory Bowel Disease (IBD) — a condition causing ongoing inflammation in the digestive system — based on standard medical tests including physical assessment, camera examination of the bowel, and tissue analysis.
  • People whose IBD is currently active, meaning symptoms are present and measurable using standard scoring tools (a score of 5 or higher on one scale for Crohn's disease, or 3 or higher on another scale for ulcerative colitis).
  • People whose stool (poo) test shows a calprotectin level above 250 micrograms per gram, which is a marker of bowel inflammation.
  • People whose IBD-related quality of life is affected, as measured by a short questionnaire, with a score of 60 or below.

Who may not be able to join:

  • People who are not able to speak and read English.
  • People who do not have regular access to the internet via a phone or computer.
  • People who have had certain bowel surgeries, such as a stoma bag (ileostomy or colostomy) or specific bowel reconnection procedures (ileoanal pouch or ileorectal anastomoses).
  • People who are scheduled to have bowel surgery in the near future.
  • People who have short bowel syndrome, a condition where part of the small intestine is missing or not working.
  • People who have another medical or mental health condition that is not currently well managed or stable.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Shirley Cohen-Mekelburg, MD, MS, University of Michigan

Phone: 734-845-5735

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
20 July 2026
Est. completion
1 March 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Participant recruitment rate; The proportion of enrolled participants that complete the study without dropout; The proportion of study assessments completed by the participant; Qualitative interviews - self-management program group

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov